ABIVAX Société Anonyme (NASDAQ:ABVX) is one of the hottest large-cap stocks of 2025. On December 16, Piper Sandler raised the firm’s price target on Abivax to $142 from $112, while maintaining an Overweight rating on the shares.
On the same day, Citizens raised the firm’s price target on ABIVAX Société Anonyme to $131 from $114, while keeping an Outperform rating on the shares. The firm highlighted that Abivax’s Q3 2025 results and operational milestones, specifically noting that the Phase 3 ulcerative colitis data released in August, reinforce the drug’s potential to redefine standard clinical care.
A day before, on December 15, Abivax reported cash and cash equivalents of €589.7 million, a substantial increase from the €144.2 million held at the end of 2024. This liquidity surge was primarily driven by a massive public offering completed on July 28, which generated ~$700.3 million (€597.2 million) in net proceeds. Consequently, Abivax has extended its projected cash runway into the fourth quarter of 2027.
The company’s net loss for the first nine months of 2025 widened to €254.1 million, compared to €136.9 million during the same period in 2024. This was largely due to an increase in R&D expenses, which rose by €25.4 million to reach €133.4 million. These costs were driven by the progression of the ABTECT Phase 3 trials for obefazimod in ulcerative colitis and Phase 2b trials for Crohn’s disease. Additionally, the company saw a spike in personnel-related expenses, specifically a €14.8 million increase in employer contributions, triggered by a significant rise in the company’s share price during Q3 2025.
ABIVAX Société Anonyme is a clinical-stage biotechnology company that develops therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.
This article is originally published at Insider Monkey.
